Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 12 May 2009
Vol. 2, Issue 70, p. ec164
[DOI: 10.1126/scisignal.270ec164]


Cancer A Second Act for Antiandrogens

Paula A. Kiberstis

Science, AAAS, Washington, DC 20005, USA

Men with advanced prostate cancer are often treated with antiandrogens—drugs that inhibit the activity of male hormones, such as testosterone, that help drive tumor growth. Many of these drugs act by functionally disrupting the androgen receptor (AR), a transcriptional regulatorof cell proliferation, but tumors eventually become resistant to the drugs by expressing higher levels of the AR. Tran et al. have developed a "second-generation" antiandrogen, a thiohydantoin called MDV3100, which binds the AR with high affinity. MDV3100 retains its anticancer activity in cell culture and in mouse models, even when AR levels are elevated. The drug appears to act both by inhibiting translocation of the AR into the nucleus and by reducing its transcriptional activity. MDV3100 is being tested in patients with advanced prostate cancer, the first group of which have shown a decline in blood levels of a marker of cancer growth, prostate-specific antigen.

C. Tran, S. Ouk, N. J. Clegg, Y. Chen, P. A. Watson, V. Arora, J. Wongvipat, P. M. Smith-Jones, D. Yoo, A. Kwon, T. Wasielewska, D. Welsbie, C. D. Chen, C. S. Higano, T. M. Beer, D. T. Hung, H. I. Scher, M. E. Jung, C. L. Sawyers, Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787–790 (2009). [Abstract] [Full Text]

Citation: P. A. Kiberstis, A Second Act for Antiandrogens. Sci. Signal. 2, ec164 (2009).

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882